DAPAGLIFLOZIN 10mg. IP + SITAGLIPTIN PHOSPHATE 100mg. IP + METFORMIN 500mg. IP

A potent antidiabetic combinational medicine that manages blood sugar levels in adults with type 2 diabetes when monotherapy or dual therapy is not sufficient. Lowers elevated blood sugar by increasing insulin sensitivity, reducing glucose production, and enhancing glucose excretion through the urine. Blocks reabsorption of filtered glucose in the kidney, increases urinary glucose excretion and reduces blood glucose levels. (Olga González Albarrán, 2013) Protects pancreatic β cells by reducing insulin levels, supporting long-term control of type 2 diabetes. (Daisuke Ito, 2021) Inhibits the enzyme dipeptidyl peptidase-4 (DPP-4), which is responsible for the degradation of incretin hormones (GLP-1 and GIP). Provides additional cardiovascular protection for patients with heart disease. Reduces the risk of kidney complications in diabetic patients. Improves glycemic control and reduces the risk of diabetes-related complications. Increases the levels of active incretin hormones, which increases insulin release and decreases glucose production by the liver. (Rana Bhattacharjee, 2023) Reduces glucose production in the liver and increases insulin sensitivity.